
    
      The Direct Flow Medical Transcatheter Aortic Valve System is indicated for symptomatic
      patients who require replacement of their native aortic valve and have a predicted operative
      mortality or serious morbidity risk of equal or greater 50% at 30 days with surgical aortic
      valve replacement or are deemed unsuitable for surgery.
    
  